Comera Life Sciences Holdings CMRA · USD

Its shares trade under the ticker CMRA. It has been listed since 15 December 2020. In the fiscal year to 31 December 2023, it reported revenue of $1.0m and a net loss of $9.0m.

Comera Life Sciences Holdings, Inc. engages in developing medicines. The company is headquartered in Woburn, Massachusetts. The company went IPO on 2020-12-15. The firm applies a knowledge of formulation science and technology to transform biologic medicines from intravenous (IV) to subcutaneous (SQ) forms. The firm is engaged in developing an internal portfolio of therapeutic product candidates using its proprietary formulation platform, SQore. Its proprietary formulation platform, SQore, is designed to transform biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. Its product programs include CLS-001, a preclinical stage bio better for Crohn’s and Ulcerative Colitis disease, and CLS-002, a preclinical stage bio better for various oncology indications. The company also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to its partners’ biologic medicines to deliver enhanced SQ formulations.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Jeffrey HackmanChairman of the Board, President, Chief Executive Officer, since 2021$935,200
• Mr. Michael CampbellChief Executive Officer, Chief Financial Officer$1.2m
• Dr. Robert MahoneyChief Scientific Officer
• Ms. Janice MccourtChief Business Officer
• Mr. Roopom BanerjeeIndependent Director$62,917
• Ms. Kirsten FlowersIndependent Director$58,542
• Mr. Stuart RandleIndependent Director$73,125
• Rev. Dr. James SherblomIndependent Director$81,250
• Mr. Edward SullivanIndependent Director$62,917

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.